Your browser doesn't support javascript.
Systematic review and meta-analysis of the effectiveness and safety of hydroxychloroquine in treating COVID-19 patients.
Yang, Tzu-Han; Chou, Chian-Ying; Yang, Yi-Fan; Chien, Chian-Shiu; Yarmishyn, Aliaksandr A; Yang, Tzu-Ying; Liu, Cheng-Hsuan; Chang, Kao-Jung; Yang, Yi-Ping; Chang, Yuh-Lih.
  • Yang TH; Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
  • Chou CY; Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
  • Yang YF; Faculty of Pharmacy, School of Pharmaceutical Sciences, National Yang-Ming University, Taipei, Taiwan, ROC.
  • Chien CS; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, ROC.
  • Yarmishyn AA; Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
  • Yang TY; School of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC.
  • Liu CH; Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
  • Chang KJ; School of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC.
  • Yang YP; Department of Dietetics and Nutrition, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
  • Chang YL; Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
J Chin Med Assoc ; 84(2): 233-241, 2021 02 01.
Article in English | MEDLINE | ID: covidwho-1066456
ABSTRACT

BACKGROUND:

Since COVID-19 outbreak, hydroxychloroquine (HCQ) has been tested for effective therapies, and the relevant researches have shown controversial results.

METHODS:

Systematic review and meta-analysis were conducted after a thorough search of relevant studies from databases. Trials that have evaluated HCQ for COVID-19 treatment were recruited for statistical analysis with fixed- and random-effect models.

RESULTS:

Nine trials involving 4112 patients were included in present meta-analysis. It was seen that HCQ-azithromycin (HCQ-AZI) combination regimen increased the mortality rate in COVID-19 (odds ratio [OR], 2.34; 95% confidence interval [CI], 1.63-3.36) patients; however, it also showed benefits associated with the viral clearance in patients (OR, 27.18; 95% CI, 1.29-574.32). HCQ-alone when used as a therapy in COVID-19 did not reveal significant changes in mortality rate, clinical progression, viral clearance, and cardiac QT prolongation. Subsequent subgroup analysis showed that HCQ treatment could decrease mortality rate and progression to severe illness in severely infected COVID-19 patients (OR, 0.27; 95% CI, 0.13-0.58). A lower risk of mortality rate was also noted in the stratified group of >14 days follow-up period (OR, 0.27; 95% CI, 0.13-0.58) compared to ≤14 days follow-up period group that conversely showed an increased mortality rate (OR, 2.09; 95% CI, 1.41-3.10).

CONCLUSION:

Our results indicated that HCQ-AZI combination treatment increased mortality rate in patients with COVID-19, but it also showed benefits associated with viral clearance in patients. HCQ-alone used for treatment has revealed benefits in decreasing the mortality rate among severely infected COVID-19 group and showed potential to be used for COVID-19 treatment in long-term follow-up period group. Accordingly, more rigorous, large-scale, and long follow-up period studies in patients with COVID-19 are needed.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Drug Treatment / Hydroxychloroquine Type of study: Cohort study / Experimental Studies / Prognostic study / Randomized controlled trials / Reviews / Systematic review/Meta Analysis Limits: Humans Language: English Journal: J Chin Med Assoc Journal subject: Medicine Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Drug Treatment / Hydroxychloroquine Type of study: Cohort study / Experimental Studies / Prognostic study / Randomized controlled trials / Reviews / Systematic review/Meta Analysis Limits: Humans Language: English Journal: J Chin Med Assoc Journal subject: Medicine Year: 2021 Document Type: Article